Jan Marsal
11 – 20 of 57
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Real-World Outcomes of Patients Starting Intravenous and Transitioning to Subcutaneous Vedolizumab in Inflammatory Bowel Disease
- Contribution to journal › Article
-
Mark
Histologic Remission in Inflammatory Bowel Disease and Female Fertility : A Nationwide Study
- Contribution to journal › Article
- 2023
-
Mark
Neue Lösung für ein altes Problem : Aktuelle Entwicklungen bei oralen Kontrastmitteln
- Contribution to journal › Scientific review
-
Mark
Alkaline sphingomyelinase (NPP7) impacts the homeostasis of intestinal T lymphocyte populations
- Contribution to journal › Article
-
Mark
Emergency subtotal colectomy rates in relation to anti-TNF therapy in inflammatory bowel disease patients : comparison of retrospective cohorts
- Contribution to journal › Article
-
Mark
Long-term outcomes of vedolizumab in inflammatory bowel disease : the Swedish prospective multicentre SVEAH extension study
- Contribution to journal › Article
- 2022
-
Mark
Response to : Response to: Irritable bowel syndrome symptoms in axial spondyloarthritis more common than among healthy controls: Is it an overlooked comorbidity?' by Proft et al.
- Contribution to journal › Debate/Note/Editorial
-
Mark
Gut dysbiosis associated with worse disease activity and physical function in axial spondyloarthritis
- Contribution to journal › Article
-
Mark
Histological remission in inflammatory bowel disease and risk of adverse pregnancy outcomes : A nationwide study
- Contribution to journal › Article
-
Mark
A novel food-based negative oral contrast agent compared with two conventional oral contrast agents in abdominal CT : a three-arm parallel blinded randomised controlled single-centre trial
- Contribution to journal › Article
